Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Tolerability of Telavancin in Cystic Fibrosis Adults With Acute Pulmonary Exacerbations
NCT03172793Phase 4Completed
- Sponsor
- Joseph L. Kuti
- Start
- Aug 2017
- Primary completion
- Apr 2019
- Modality
- Peptides, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label trial of telavancin in cystic fibrosis (CF) and Staphylococcus aureus infection (3 arms), sponsored by Joseph L. Kuti. Primary endpoints: Telavancin Clearance at 72 hours and Telavancin Volume of Distribution at 72 hours. Started Aug 2017; status: completed.
02
Drugs
telavancin
03
Conditions
cystic fibrosis (CF)Staphylococcus aureus infection
Beyond the preview
Go deeper on NCT03172793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03172793.